Alongside currently FDA-approved new approaches targeting the host immune tumor surveillance system (anti-PD-1/anti-PD-L1), the already compromised DNA repair machinery with BRCA1/2 mutations (PARP inhibitors), and topoisomerase I inhibitors (sacituzuamb), a logical next opportunity is to target SIAH in the K-RAS/EGFR pathway in malignant TNBC. The gene discussed is KRAS; the disease is neoplasm.